Rani Therapeutics Holdings (RANI) Return on Capital Employed (2021 - 2026)
Rani Therapeutics Holdings' (RANI) quarterly Return on Capital Employed came in at 83.67% in Q1 2026, up 41678.0% year-on-year from N/an in Q1 2025, and up 52.58% quarter-over-quarter from 176.45% in Q4 2025.
Rani Therapeutics Holdings (RANI) Return on Capital Employed (2021 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 83.67% for Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 41678.0% year-over-year to 83.67% in Q1 2026; TTM through Mar 2026 was 83.67%, a 41678.0% increase from a year earlier, with the FY2025 full-year figure at 109.59%, up 8510.0% from the prior year.
- Return on Capital Employed grew to 83.67% in Q1 2026 per RANI's latest filing, from 176.45% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 44192.83% in Q2 2025 and bottomed at 500.45% in Q1 2025.
- The 5-year median for Return on Capital Employed is 83.67% (2026), against an average of 2517.79%.
- Biggest YoY gain for Return on Capital Employed was 4437338 bps in 2025; the steepest drop was 35020 bps in 2025.
- Year by year, Return on Capital Employed stood at 61.42% in 2022, then sank by 92 bps to 117.64% in 2023, then tumbled by 124 bps to 263.99% in 2024, then soared by 33 bps to 176.45% in 2025, then jumped by 53 bps to 83.67% in 2026.
- Per Business Quant, the three latest RANI Return on Capital Employed figures stand at 83.67% (Q1 2026), 176.45% (Q4 2025), and 795.18% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Rani Therapeutics Holdings | 160.20 Mn | 167.33 Mn | - | -83.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -83.67% |
| Dec 31, 2025 | -176.45% |
| Sep 30, 2025 | 795.18% |
| Jun 30, 2025 | 44,192.83% |
| Mar 31, 2025 | -500.45% |
| Dec 31, 2024 | -263.99% |
| Sep 30, 2024 | -221.12% |
| Jun 30, 2024 | -180.56% |
| Mar 31, 2024 | -150.26% |
| Dec 31, 2023 | -117.64% |
| Sep 30, 2023 | -100.75% |
| Jun 30, 2023 | -81.47% |
| Mar 31, 2023 | -68.17% |
| Dec 31, 2022 | -61.42% |
| Sep 30, 2022 | -59.88% |
| Jun 30, 2022 | -67.74% |
| Mar 31, 2022 | -52.06% |
| Dec 31, 2021 | -40.33% |
| Sep 30, 2021 | -42.38% |